Hans Hammers, MD, PhD

Dr. Hammers discusses future management for advanced RCC, unmet needs, and emerging data being monitored.

Provide perspective on quality-of-life observations with different IO-TKI regimens and supporting evidence.

Dr. Hammers outlines his thought process around TKI/ICI dose modifications vs discontinuations with toxicity and discusses toxicity management recommendations.

Dr. Hammers shares his experience with high-grade AEs in IO-TKI treated patients and how toxicities are mitigated/managed.

Dr. Hammers explains factors involved in decision-making between immunotherapy-based treatment options.

Dr. Hammers discusses recent efficacy and safety data updates from CHECKMATE-214, KEYNOTE-426, and CHECKMATE-9ER trials.

Dr. Hammers summarizes key efficacy findings from the CLEAR study of pembrolizumab + lenvatinib vs sunitinib.

Dr. Hammers provides a perspective on the appropriateness of initial pembrolizumab + lenvatinib therapy based on guidelines.

Dr. Hammers discusses initial impressions of the case presentation, comparing it to typical advanced RCC, and reviewing risk factors.

In the fifth article of this series, Hans Hammers, MD, PhD, outlines established treatment paradigms and discusses clinical trial data and ongoing research that are informing the future treatment landscape of advanced renal cell carcinoma.

Hans Hammers, MD, PhD, discusses the evolving treatment paradigms in patients with advanced renal cell carcinoma and how recent clinical trial data may optimize future treatment selections.

Closing out their discussion on advanced RCC, expert hematologist/oncologists offer key takeaways from their discussion and look toward future treatment evolution in the first-line setting.

Shared insight on the data from the COSMIC-313 trial and the potential for first-line triplet regimens in patients with advanced clear cell renal cell carcinoma.

Panelists identify second-line treatment options they would consider in advanced clear cell RCC if a patient progresses following first-line therapy.

Expert hematologist/oncologists consider the potential role for adjuvant immunotherapy in patients with advanced clear cell renal cell carcinoma.

Focused discussion on the selection of first-line therapy for advanced clear cell renal cell carcinoma based on sites of metastasis.

Expert panelists consider the importance of quality of life when selecting first-line treatment regimens for patients with advanced clear cell renal cell carcinoma.

Shared insight on optimal dosing strategies with first-line tyrosine kinase inhibitor and immunotherapy combinations for patients with advanced clear cell renal cell carcinoma.

Sumanta Pal, MD, an expert hematologist/oncologist, evaluates the combination of cabozantinib + nivolumab as first-line therapy for advanced clear cell renal cell carcinoma.

Centering discussion around the combination of lenvatinib + pembrolizumab in advanced clear cell RCC, Hans Hammers, MD, considers the role of this combination regimen in the first-line treatment setting.

Expert hematologist/oncologist Brian Rini, MD, spearheads a comprehensive discussion on the broad treatment landscape for advanced clear cell renal cell carcinoma.

Hans Hammers, MD, PhD, associate professor at the University of Texas Southwestern Medical Center, discusses what he believes is most important in future investigation for the treatment of patients with renal cell carcinoma. With combination therapies on the rise in the field of kidney cancers, new pivotal and early clinical trials are constantly arising looking at new combination regimens.